Abstract 7387: Trends in cancer prevalence among people with type 2 diabetes: an analysis using National Health Interview Survey
Authors: Pranali G. Patel, Chaitali S. Dagli, Nada Al-Antary, Mrudula Nair, Abdulghafoor Alani, Oluwole A. Babatunde, Nosayaba Osazuwa-Peters, Eric Adjei Boakye
Journal: Cancer Research (2025)

Abstract Background: Type 2 diabetes (T2D) is associated with an increased risk of cancers including colorectal (CRC), breast, endometrial, liver, pancreatic, kidney, bladder, lung, and esophageal. Research indicates that individuals with T2D experience a higher incidence of CRC, potentially due to shared risk factors or biological pathway. This study aims to examine and compare trends in the prevalence of CRC to other cancers (in this study includes breast, endometrial, liver, pancreatic, kidney, bladder, lung, and esophageal) among respondents diagnosed with T2D. Methods: We analyzed data from the 2013-2023 National Health Interview Survey (NHIS), a nationally representative, cross-sectional survey of the U.S. non-institutionalized population that employs a multistage probability sampling design. Adults aged &amp;gt;18 years with a T2D diagnosis, currently on medications, and diagnosed with cancer were included. Joinpoint regression was used to estimate trends in CRC prevalence compared to other cancers among individuals with T2D through annual percent change (APC). Results: The study included a total weighted sample of 11, 766, 072 respondents, consisting of 1, 893, 687 individuals with CRC and 9, 872, 385 individuals with other cancers. Most respondents were aged 65+ (70%), female (66%), non-Hispanic White (71%) and married (56%). Overall, we observed an increase of 9% per year in the proportion of CRC cases between 2013 and 2015, although not statistically significant, followed by a significant decrease of 4% per year between 2015 and 2023. In contrast, the proportion of other cancer cases remained relatively stable. For females with CRC, the proportion increased by 25% per year from 2013 to 2015, although not statistically significant, but significantly decreased by 8% per year from 2015 to 2023. While among females with other cancers, the proportion decreased by 4% per year between 2013 and 2015, although not statistically significant, but significantly increased 1% per year between 2015 and 2023. The proportion of males with CRC increased 1% per year from 2013 to 2016 and later decreased by 4% per year from 2016 to 2023; neither of which were statistically significant. The proportion of other cancers among males significantly increased by 2% per year from 2013 to 2021 and remained stable between 2021 and 2023. Conclusion: CRC prevalence has declined overall since 2015 among individuals with T2D. However, sex differences persist, with notable decrease among females in the same time frame. Meanwhile, other cancer trends have remained stable. These findings highlight the complex relationship between T2D and cancer, which may be influenced by various factors such as gender, age, and possible common underlying mechanisms. Further research is needed to explore the underlying causes of these trends and disparities among males and females. Citation Format: Pranali G. Patel, Chaitali S. Dagli, Nada Al-Antary, Mrudula Nair, Abdulghafoor Alani, Oluwole A. Babatunde, Nosayaba Osazuwa-Peters, Eric Adjei Boakye. Trends in cancer prevalence among people with type 2 diabetes: an analysis using National Health Interview Survey [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 7387.